Publications by authors named "I Ricciardelli"

The field of cell and gene therapy (GT) is expanding rapidly and there is undoubtedly a wave of enthusiasm and anticipation for what these treatments could achieve next. Here we assessed the worldwide landscape of GT assets currently in early clinical development (clinical trial phase 1/2 or about to enter clinical trial). We included all gene therapies, i.

View Article and Find Full Text PDF

Background: X-linked lymphoproliferative disease 1 arises from mutations in the SH2D1A gene encoding SLAM-associated protein (SAP), an adaptor protein expressed in T, natural killer (NK), and NKT cells. Defects lead to abnormalities of T-cell and NK cell cytotoxicity and T cell-dependent humoral function. Clinical manifestations include hemophagocytic lymphohistiocytosis, lymphoma, and dysgammaglobulinemia.

View Article and Find Full Text PDF

Background: Mutations in the perforin 1 (PRF1) gene account for up to 58% of familial hemophagocytic lymphohistiocytosis syndromes. The resulting defects in effector cell cytotoxicity lead to hypercytokinemia and hyperactivation with inflammation in various organs.

Objective: We sought to determine whether autologous gene-corrected T cells can restore cytotoxic function, reduce disease activity, and prevent hemophagocytic lymphohistiocytosis (HLH) symptoms in in vivo models.

View Article and Find Full Text PDF

Substantial efforts have been made in recent years to investigate the horizontal variability of air pollutants at regional and urban scales and epidemiological studies have taken advantage of resulting improvements in exposure assessment. On the contrary, only a few studies have investigated the vertical variability and their results are not consistent. In this study, a field experiment has been conducted to evaluate the variation of concentrations of different particle metrics and gaseous pollutants on the basis of floor height at a high rise building.

View Article and Find Full Text PDF
Article Synopsis
  • Mature T cell cancers are aggressive and hard to treat due to the difficulty in distinguishing between malignant and healthy T cells.
  • Researchers discovered that T cell receptor β-chain constant domains (TRBC1 and TRBC2) are expressed distinctly in these cells, which led to the development of a specific antibody targeting TRBC1.
  • Anti-TRBC1 chimeric antigen receptor (CAR) T cells demonstrated effectiveness in killing malignant T cells while sparing normal T cells, offering a promising approach for targeted immunotherapy.
View Article and Find Full Text PDF